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tively. ConClusions: Hospitalizations for patients with HF are costly. On average 
hospitalizations due to worsening HF could range from $23,800 to $48,500 depending 
on the type of coverage. The costs of hospitalizations were higher in patients with 
commercial insurance when compared to Medicare advantage patients.
PCV109
Current resourCe utilization Patterns in MediCare BenefiCiaries 
diagnosed With heart failure
Patel H.1, Sharma P.2, Maya J.1, Kilgore M.2, Kielhorn A.1
1Amgen, Thousand Oaks, CA, USA, 2Univeristy of Alabama at Birmingham, Birmingham, AL, 
USA
objeCtives: To estimate annual hospitalization rate and associated direct costs 
for Medicare beneficiaries with heart failure (HF). Methods: A 5% (n=3,493,434) 
national sample of Medicare beneficiaries was used to identify individuals with 
first observed primary inpatient claim for HF (ICD-9: 428.xx) between 07/01/2005 
and 12/31/2011. Patients having HF diagnoses in the 6 months prior to first observed 
claim were excluded. Patient demographics, use of HF medications and medical 
devices were reported. Annual hospitalization rate and associated total costs (the 
Centers for Medicare and Medicaid Services payment, as well as patient out-of-
pocket costs) were calculated. In order to account for varying lengths of follow-up, 
a per patient-year estimation method was used to calculate the cumulative rate 
of hospitalizations. Cumulative hospitalization rates and associated costs were 
estimated for all-cause hospitalizations, cardiovascular (CV) hospitalizations and 
HF-related hospitalizations. Results: A total of 63,678 patients met the study cri-
teria. Mean age was 82 years and 61% of patients were women. Among patients 
with part D coverage (n=35,788), 64.6% of patients used β blockers. On average, 
patients were hospitalized 2.19 times per patient-year for all-cause. Patients were 
hospitalized on average 1.02 times per patient-year for HF- and 1.30 times per 
patient-year for CV-related hospitalization. The costs associated with first observed 
all-cause hospitalization were $14,500, for CV-related hospitalization was $17,300 
and for HF-related hospitalization were approximately $16,000. ConClusions: 
CONCLUSIONS: Patients with HF who have been hospitalized had frequent subse-
quent hospitalizations. On an average, these individuals experienced 2 all-cause 
hospitalizations per year, one of them being due to worsening of HF. These hos-
pitalizations were costly, with costs ranging from $14,000 to $17,300 per episode.
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objeCtives: To identify baseline demographics and clinical characteristics asso-
ciated with healthcare costs among patients with atherosclerotic cardiovascular 
disease (ASCVD). Methods: This retrospective cohort study identified newly 
diagnosed ASCVD patients aged ≥ 18 years using claims data from the HealthCore 
Integrated Research Database (HIRDSM) between 1/1/07 and 11/30/12 (index 
date= first ASCVD diagnosis date). Patients had both ≥ 12 month pre- and post-
index insurance enrollment, valid baseline lipid panel values, and no baseline lipid 
lowering medication use. Costs were adjusted to 2013 U.S. dollar values. Bivariate 
analyses and generalized linear models with gamma distribution and log link were 
used to examine baseline factors associated with 12 month follow-up all-cause and 
ASCVD-related healthcare costs. Results: In the regression model for all-cause 
healthcare costs (N= 26,388), older age, plan region including South and West (vs. 
Midwest), higher Quan-Charlson Comorbidity Index, index acute coronary syndrome 
(ACS), ischemic stroke or transient ischemic attack, baseline depression, pain, obe-
sity, and chronic kidney disease, baseline use of antihypertensive agents, antidia-
betic medications, and digoxin, and higher baseline all-cause healthcare costs were 
positively associated with follow-up all-cause healthcare costs (p< 0.05). In addi-
tion, female, Northeast plan (vs. Midwest), Health Maintenance Organization (vs. 
Preferred Provider Organization), Medicare Advantage plans, index coronary heart 
disease (except for ACS) or peripheral artery disease, baseline dyslipidemia, and 
baseline goal attainment of low-density lipoprotein cholesterol (< 100 mg/dL), high-
density lipoprotein cholesterol ( > 40/50 mg/dL for males and females respectively), 
triglycerides (< 150 mg/dL), and total cholesterol level (< 200 mg/dL) were negatively 
associated with follow-up all-cause healthcare costs (p< 0.05). Similar findings 
were reported for ASCVD-related healthcare costs (N= 26,376). ConClusions: As 
expected, age, gender, baseline comorbid conditions, baseline use of specific medi-
cations, baseline lipid profiles, and more severe index ASCVD were significantly 
associated with all-cause and ASCVD-related healthcare costs. Geographic location 
and health insurance type also played a significant role in healthcare costs among 
ASCVD patients.
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objeCtives: To estimate the cumulative annual hospitalization rate for patients 
with heart failure (HF). Methods: A retrospective analysis was undertaken using a 
large US claims database, the Optum Research Database. A per patient-year estima-
tion method was used to calculate a cumulative rate of hospitalization to account for 
varying lengths of follow-up. Patients ≥ 18 years, with a first observed inpatient heart 
failure claim (ICD-9: 428.xx; in primary position) between 01/01/08 and 06/30/13 were 
included. Patients having an inpatient claim for HF in the 2 months prior to the first 
tatin and simvastatin in early 2006, respectively, created a unique opportunity to 
examine how patient cost-sharing differentials for brand-name and generic drugs 
impact therapeutic substitution and medication adherence with statins. Methods: 
Using the 2006 5% Medicare files we identified continuous fee-for-service Part D 
covered patients with hyperlipidemia (ICD-9-CM 272.0-272.4) using the brand-
name statins (atorvastatin or rosuvastatin) between 1/1/2006 and 3/31/2006. The 
quasi-experimental study examined changes in outcomes across the pre- (prior to 
coverage gap) and post- (during coverage gap) periods for non-low income subsidy 
(non-LIS) patients with generic-only coverage in gap who faced substantial increases 
in brand-name statin cost sharing ($28 to $82 per 30-day supply) but no changes in 
generic cost-sharing from the pre- to post-period compared to a control group of 
LIS patients who faced no changes in brand-name ($3) or generic ($1) cost-sharing 
in the pre- and post-periods. The two groups were propensity-score matched on 
sociodemographics and clinical characteristics. Difference-in-difference regressions 
were used to examine impact on use of brand-name statins, generic statins, and 
overall any statin use. In addition, overall adherence (PDC> 0.80) to and discontinua-
tion (30-day gap) of statins was also examined. Results: Compared to LIS patients, 
non-LIS patients had a larger decline in brand-name statin use (-0.24 30-day-sup-
ply/month, p< 0.001), smaller increase in generic statin use (+0.06 30-day-supply/
month, p< 0.001), and hence, an overall drop in any statin use (-0.18 30-day-supply/
month, p< 0.001). Correspondingly, a decrease in adherence (OR: 0.81,p< 0.001) and 
increase in discontinuation (OR: 1.62,p< 0.001) on any statins was observed in non-
LIS patients relative to LIS patients. ConClusions: A substantial brand/generic 
cost-sharing differential was associated with therapeutic substitution of brand-
name statins with generic statins; however, it also resulted in declines in adherence 
and increases in discontinuation of statins.
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objeCtives: Intracoronary atherothrombosis complicates percutaneous coronary 
intervention (PCI). Cangrelor, a novel, intravenous P2Y12 inhibitor reduced the risk 
of death, MI, ischemia-driven revascularization and stent thrombosis at 48 hours 
by 22% compared to clopidogrel in the CHAMPION PHOENIX Trial. An economic 
sub-study was designed, from the perspective of the US healthcare system, to 
determine the direct medical costs during index hospitalization among cangrelor 
vs. clopidogrel patients and the subgroup receiving bivalirudin as antithrombin 
therapy. Methods: Hospital bills were collected from participating US sites in the 
CHAMPION PHOENIX trial. Hospital costs were determined by multiplying itemized 
hospital charges and the cost-center specific cost-to-charge ratios obtained from 
hospital’s Medicare Cost Report (MCR). A model predicting in-hospital costs was 
developed by utilizing multivariate imputation by chained equations (MICE) meth-
odology. The costs were imputed for patients where clinical but not economic data 
were available. After imputation, the index hospital costs from entire US population 
were compared between treatment groups. Results: Thirty-eight US sites were 
invited and 22 participated. One site was excluded due to incomplete MCR. Hospital 
bills from 1117 patients (27.3% of 4,097 CHAMPION PHOENIX US population) were 
utilized. Patients’ baseline characteristics and complications were similar to the 
rest of US population. After the MICE imputation, the index hospitalization costs of 
patients receiving cangrelor and clopidogrel were not statistically different ($11,755 
cangrelor vs. $11,914 clopidogrel, P= NS, difference= $159) even when bivalirudin as 
the anticoagulant was utilized ($12,941 cangrelor/bivalirudin vs. $13,216 clopidogrel/
bivalirudin, P= NS, difference= $275). Data also shows a numerical saving of $109 
for catheterization laboratory costs among cangrelor-treated patients ($9,030 vs. 
$9,139, P= NS) with similar results among bivalirudin subgroup. ConClusions: This 
analysis reveals similar direct medical costs, from the perspective of the US health-
care system, for cangrelor patients (with or without bivalirudin) during the index 
hospitalization and catheterization laboratory in the CHAMPION PHOENIX trial.
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objeCtives: To estimate the mean cost per episode of hospitalization for patients 
with heart failure (HF). Methods: A retrospective analysis was undertaken using a 
large US claims database, the Optum Research Database. Adult patients with a first 
observed inpatient HF claim (ICD-9: 428.xx; in primary position) between 01/01/08 and 
06/30/13 were included. Patients having an inpatient claim for HF in the 2 months 
prior to the first observed claim were excluded. Direct costs included the amount 
paid by insurance plan, co-ordination of benefits and patient out-of-pocket costs. 
Cumulative hospitalization rates were estimated for all HF-related hospitaliza-
tions, cardiovascular (CV) hospitalizations and all-cause hospitalizations, within 
the study period. Results were further categorized by types of insurance, specifi-
cally, commercial and Medicare advantage. Results: A total of 85,938 patients met 
the study criteria of which 68.3% (n= 58,732) had Medicare Advantage coverage and 
31.7% (n= 27,206) had commercial insurance. The mean age was 63 years for patients 
with commercial insurance and 77 years for those with Medicare advantage. For 
the total population (commercial + Medicare advantage), the mean direct costs 
were approximately $30,900 for a HF- related hospitalization, $30,400 for CV-related 
hospitalization, and $25,400 for an all-cause hospitalization. For patients with com-
mercial insurance, the mean costs were approximately $48,500, $47,700 and, $40,000 
for a HF-related, CV-related, and all-cause hospitalization episode, respectively. For 
patients with Medicare advantage, the mean costs were approximately $23,800, 
$23,400 and $19,600 for HF-related, CV-related, and all-cause hospitalizations, respec-
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objeCtives: To understand why dronedarone failed to unseat amiodarone as the 
primary antiarrhythmic treatment of choice for persistent AF, thus uncovering the 
clinical outcome requirements for a future AF therapy to achieve optimal market 
access. Methods: Review published HTA reports and clinical trial outcomes for 
dronedarone to assess market access outcomes and associated Payer rationale for 
decision-making. Interview ten (10) managed care medical directors and AF key 
opinion leaders (KOLs) in US and thirteen (13) ex-Payers and AF KOLs in Europe 
(mix of stakeholders encompassing France, Germany, Italy, Spain, and UK) for vali-
dation and gap filling. Results: Driven by benefits in all efficacy outcomes other 
than cardiovascular-related hospitalizations, Payers perceive amiodarone as more 
efficacious than dronedarone. The significant number of deaths during the high-
risk PALLAS study crippled the safety image of dronedarone. Finally, a prohibitive 
price at launch contributed to a multiplicity of negative HTA assessments. In order 
to succeed where dronedarone failed and qualify as a step function increase over 
the standard-of-care amiodarone, Payers require at least: 40% reduction in AF recur-
rence; 30% relative risk reduction in hospitalizations compared to amiodarone; 
and fewer than 1% deaths as part of the clinical evidence package. Lower rates of 
bradyarrhythmia, liver toxicity, and no proarrhythmia will drive a favorable regula-
tory safety evaluation compared to amiodarone. ConClusions: The sub-optimal 
market access and relatively low utilization of dronedarone resulted primarily from 
a failure to demonstrate an improvement in recurrence as compared to amiodar-
one, as well as a significant number of deaths during pivotal trials. Manufacturers 
considering development of novel antiarrhythmics should strive for equivalent 
efficacy but superior safety to amiodarone if a 40% reduction in recurrence is not 
clinically feasible.
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objeCtives: Existing heart failure standard of care (SoC) provides symptom 
relief with no impact on changing the disease course. This research assessed 
Payers’ perceived value and willingness to pay (WTP) for a novel oral therapy 
with significant improvement on top of SoC and a cell therapy providing poten-
tial disease modifying outcomes and enhanced mortality benefit. Methods: An 
online survey with 22 US and EU-5 Payers assessing perceptions of current SoC 
therapies was conducted. A systematic evaluation of heart failure pharmaceuti-
cal, biologic and cell based therapies under clinical development was performed 
from which two hypothetical product profiles were developed: 1) a novel orally 
administered therapy; and 2) a recombinant cell based treatment via intramyo-
cardial infusion. Profiles were then tested by 30 in-depth interviews with US and 
EU-5 Payers. Results: Payer preference is based on the technology’s ability to 
meet efficacy targets treating the broadest heart failure patient segments. The 
oral agent was the preferred agent due to the clinical feasibility to develop with a 
WTP per day of US $8, UK £ 3 and EU € 5 based on efficacy: ≥ 28% RRR composite 
of CV death and HF hospitalizations; ≥ 25% RRR in CV mortality and ≥ 25% RRR 
in all-cause mortality. The cell based therapy was cited as the most promising 
by improving symptoms and changing disease course with a WTP per treatment 
of US $6,500, UK £1,200 and EU € 1,000 based on efficacy: improvement of NYHA 
functional class in ≥ 15% of patients in 1 year and ≥ 15% improvement in heart 
function. ConClusions: Payers see novel oral therapies as highly feasible and 
efficient in treating the broadest population and are willing to pay a premium. 
However, technologies that are disease modifying, reduce hospitalizations, and 
provide a significant mortality benefit are most desirable notwithstanding the 
considerable cost of treatment.
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objeCtives: Chest pain complaint is a common and difficult condition to diagnose 
due to the diversity of the underlying conditions that could cause it. The objective 
of this study is to examine the impact of the uncertainty in diagnosis on resource 
utilization using chest pain as an example. Methods: Cross-sectional explora-
tion of the National Hospital Ambulatory Medical Care Survey (NHAMCS) for U.S. 
emergency departments conducted between 2006 and 2010. Patients whom primary 
reason for visiting the ED was chest pain were classified into two categories based 
on the physicians’ final diagnosis upon discharge: 1) well-defined diagnosis and 
2) ill-defined diagnosis(unspecific chest pain(ICD9= 786.5X)). Differences between 
groups in resource utilization which includes the number of procedures, diagnos-
tics and length of visits were examined using bivariate analyses. Results: There 
were 8,662 ER visits, representing more than 33 million ER visits between 2006 and 
2010 where the chief complaint was chest pain. More than half of those patients 
(54%) had an ill-defined diagnosis upon discharge. No difference between the two 
groups were detected in gender (female = 53%), race (72.8% white, 23.6% black and 
3.6% others), education, subsequent hospital admission (30%) and number of pro-
cedures (mean= 0.7, STD= 0.03). Patients with ill-defined diagnosis, however, were 
more likely to be admitted to observation units (5.8% vs. 1.9%, p< 0.001), received 
more blood tests (p< 0.001), diagnostics (p< 0.001), imaging procedures (44.1% vs. 
33.6%, p< 0.001) specifically X-ray (41.8% vs. 31.5%, p< 0.001) and also had higher 
length of visits (269.5 minutes vs. 241.6 minutes, p< 0.001). ConClusions: The 
uncertainty dictated by the nature of chest pain symptom and the wide array of its 
underlying conditions inflict higher burden on the U.S. healthcare system. Better 
diagnostic techniques with higher sensitivity and specificity are badly needed to 
alleviate this issue.
observed claim were excluded. Cumulative rates were estimated for all HF-related 
hospitalizations, cardiovascular (CV) hospitalizations and all-cause hospitalizations, 
within the study period. Results were further categorized by types of insurance, spe-
cifically, commercial and Medicare advantage. Results: A total of 85,938 patients 
met the study criteria of which 68.3% (n= 58,732) had Medicare advantage coverage 
and 31.7% (n= 27,206) had commercial insurance. The mean age was 63 years for 
patients with commercial insurance and 77 for those with Medicare advantage. 
For the total population (commercial + Medicare advantage), the cumulative hos-
pitalization rate, inclusive of the first hospitalization, was 1.07 per patient-year for 
HF-related hospitalizations, 1.16 for CV-related hospitalizations (inclusive of HF) 
and 1.76 for all-cause hospitalizations. Cumulative hospitalization rates for patients 
with commercial insurance were 0.93, 1.00 and 1.52 for HF-related, CV, and all-cause 
hospitalizations, respectively. For patients with Medicare advantage coverage, the 
cumulative hospitalization rates were 1.14, 1.24 and 1.88 for HF-related, CV, and 
all-cause hospitalizations, respectively. ConClusions: Patients with heart failure 
who have been hospitalized have frequent subsequent hospitalizations. On average, 
these individuals were hospitalized at least once a year for worsening heart failure, 
irrespective of their coverage.
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Burden aMong u.s. CardioVasCular disease Patients in the Veterans 
health adMinistration PoPulation
Mao X.1, Shrestha S.2, Baser O.3, Wang L.2
1University of Texas at Dallas and STATinMED Research, Plano, TX, USA, 2STATinMED Research, 
Plano, TX, USA, 3STATinMED Research, The University of Michigan, MEF University, Ann Arbor, 
MI, USA
objeCtives: To assess health care resource utilization and costs among U.S. 
patients diagnosed with cardiovascular disease (CVD) using the Veterans Health 
Administration (VHA) dataset. Methods: Patients diagnosed with CVD or who 
underwent CVD-related procedures were identified (International Classification 
of Disease, 9th Revision, Clinical Modification [ICD-9-CM] diagnosis codes 410, 412, 
411.1, 411.81, 411.89, 434, 436, 437.0, 437.1, 438, 997.02, 435 and 428, ICD-9 procedure 
codes 00.66, 36.09 and current procedural terminology [CPT]-4 codes 33503-33545) 
using the VHA dataset from 01OCT2008 through 30SEPT2012. The initial diagnosis 
date was designated as the index date. Patients without a CVD diagnosis, who were 
of the same age, race and gender as study CVD patients, were identified for com-
parison. An index date was selected at random to minimize bias. Patients in both 
groups were required to be age ≥ 18 years with continuous medical and pharmacy 
benefits 1 year pre- and post-index date. One-to-one propensity score matching 
(PSM) was used to compare health care resource utilization and costs between the 
CVD and comparison groups during the follow-up period, adjusting for baseline 
demographic and clinical characteristics. Results: After risk-adjusted analysis 
using PSM, 536,125 patients in each group were matched. More CVD patients had 
inpatient admissions (14.40% vs. 1.43%, p< 0.0001) and emergency room (14.89% 
vs. 3.66%, p< 0.0001), outpatient office (60.90% vs. 47.19%, p< 0.0001), outpatient 
(61.35% vs. 47.99%, p< 0.0001) and pharmacy visits (64.41% vs. 54.89%, p< 0.0001) 
compared to those without CVD. CVD patients also incurred higher costs. Costs 
were significantly higher for CVD patients than for those without CVD ($8,248 
vs. $1,638, p< 0.0001). ConClusions: CVD patients in the VHA population more 
frequently utilized health care resources and incurred higher costs than those 
without CVD.
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objeCtives: By estimating the direct medical cost of hemorrhagic stroke inpatients 
with urban basic health insurance scheme(exclude new rural cooperative medical care 
system )from 2010 to 2012 in China, we try to provide evidence for the government to 
manage the illness more effectively. Methods: The inpatients with discharge diag-
nosis disease coded with ICD-10 (I60,I61,I62) were extracted from the China Health 
Insurance Research Association claim database which includes a nationwide, cross-
sectional sampling of inpatients from 2010 to 2012.In this paper, the descriptive statis-
tical analysis was used. Results: The analysis included 6715 patients(male:63.49%), 
patients with older than 50 years accounted for 82.87%(n= 5565). From 2010 to 2012, 
the average hospitalization expenses of each visits were 24656.0,23131.4 and 24995.0 
yuan(the average hospitalization expenses in the whole country:8849,8852and 9732 
yuan).Third-level hospitals, second-level hospitals and under second-level hospitals 
accounted for 57.85%,34.22% and 9.41%, respectively; total hospitalization expenses 
accounted for 71.35%, 22.69% and 5.85%; the average hospitalization expenses were 
30303.49, 16446.19 and 18624.96 yuan.78.78% of inpatient hospital expenses were 
occupied by patients who were over 50 years old. Reimbursement by urban basic 
health insurance scheme in 2010, 2011 and 2012 was 66.47%, 70.59% and 65.08%, 
respectively; while the corresponding patient co-pay burden was 33.53%, 29.41% and 
34.92%. ConClusions: The average hospitalization expenses of each visits of hem-
orrhagic stroke was greater than the national average inpatients costs, although the 
reimbursement by urban basic health insurance scheme had increase dramatically, 
but the out-of-pocket spending was still high, especially for the poor.60% of inpatients 
went to third-level hospital, needing to establish patient grading care system at once, 
going back to community hospitals after recovery, which may reduce the burden of 
medical institutions and patients .
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